Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease

被引:0
作者
Franc Llorens
Niels Kruse
André Karch
Matthias Schmitz
Saima Zafar
Nadine Gotzmann
Ting Sun
Silja Köchy
Tobias Knipper
Maria Cramm
Ewa Golanska
Beata Sikorska
Pawel P. Liberski
Raquel Sánchez-Valle
Andre Fischer
Brit Mollenhauer
Inga Zerr
机构
[1] University Medical Center Göttingen,Clinical Dementia Center, Department of Neurology
[2] German Center for Neurodegenerative Diseases (DZNE),Institute for Neuropathology
[3] Site Göttingen,Department of Epidemiology
[4] University Medical Center Göttingen,Department of Molecular Pathology and Neuropathology
[5] Helmholtz Centre for Infection Research,Creutzfeldt
[6] Medical University of Lodz,Jakob disease unit. Alzheimer’s disease and other cognitive disorders unit. Hospital Clínic
[7] Institut d’Investigacions Biomèdiques August Pi i Sunyer,Paracelsus
[8] Center for Parkinsonism and Movement Disorders,Elena Klinik
[9] University Medical Center Göttingen,Department of Neurosurgery
来源
Molecular Neurobiology | 2018年 / 55卷
关键词
Sporadic Creutzfeldt-Jakob; α-Synuclein; Cerebrospinal fluid; Biomarkers; Electrochemiluminescence; ELISA;
D O I
暂无
中图分类号
学科分类号
摘要
The analysis of cerebrospinal fluid (CSF) biomarkers gains importance in the differential diagnosis of prion diseases. However, no single diagnostic tool or combination of them can unequivocally confirm prion disease diagnosis. Electrochemiluminescence (ECL)-based immunoassays have demonstrated to achieve high diagnostic accuracy in a variety of sample types due to their high sensitivity and dynamic range. Quantification of CSF α-synuclein (a-syn) by an in-house ECL-based ELISA assay has been recently reported as an excellent approach for the diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD), the most prevalent form of human prion disease. In the present study, we validated a commercially available ECL-based a-syn ELISA platform as a diagnostic test for correct classification of sCJD cases. CSF a-syn was analysed in 203 sCJD cases with definite diagnosis and in 445 non-CJD cases. We investigated reproducibility and stability of CSF a-syn and made recommendations for its analysis in the sCJD diagnostic workup. A sensitivity of 98% and a specificity of 97% were achieved when using an optimal cut-off of 820 pg/mL a-syn. Moreover, we were able to show a negative correlation between a-syn levels and disease duration suggesting that CSF a-syn may be a good prognostic marker for sCJD patients. The present study validates the use of a-syn as a CSF biomarker of sCJD and establishes the clinical and pre-analytical parameters for its use in differential diagnosis in clinical routine. Additionally, the current test presents some advantages compared to other diagnostic approaches: it is fast, economic, requires minimal amount of CSF and a-syn levels are stable along disease progression.
引用
收藏
页码:2249 / 2257
页数:8
相关论文
共 100 条
  • [1] Puoti G(2012)Sporadic human prion diseases: molecular insights and diagnosis Lancet Neurol 11 618-628
  • [2] Bizzi A(2003)Sporadic and familial CJD: classification and characterisation Br Med Bull 66 213-239
  • [3] Forloni G(2007)Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance Brain 130 1350-1359
  • [4] Gambetti P(2016)Rapidly progressive dementia Contin Lifelong Learn Neurol 22 510-537
  • [5] Kong Q(2011)Rapidly progressive Alzheimer disease Arch Neurol 68 1124-1130
  • [6] Zou W(2012)Diagnosis and treatment of rapidly progressive dementias Neurol Clin Pract 2 187-200
  • [7] Heinemann U(2006)CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease Neurology 67 637-643
  • [8] Krasnianski A(1998)Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease Ann Neurol 43 32-40
  • [9] Meissner B(2012)Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years Brain 135 3051-3061
  • [10] Geschwind MD(2002)Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease Neurology 58 192-197